Cell Marque Portfolio

PAX-8 (MRQ-50)

Mouse Monoclonal


This protein is a member of the paired box (PAX) family of transcription factors. Members of this gene family typically encode proteins which contain a paired box domain, an octapeptide, and a paired-type homeodomain. This nuclear protein is involved in thyroid follicular cell development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular carcinomas, and atypical thyroid adenomas. PAX-8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes, and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX-8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. Studies have also found PAX-8 expression in renal tubules as well as renal cell carcinoma, nephroblastoma, and seminoma. A study by Tong et al. showed that 98% of clear cell RCCs, 90% of papillary RCCs, and 95% of oncocytomas were positive for anti-PAX-8 with frequencies of positivity that are similar to anti-PAX-2. Therefore, anti-PAX-8 may be used as an additional immunohistochemical marker for renal epithelial tumors. Normal lung and lung carcinomas do not express PAX-8. Similarly, the absence of expression of PAX-8 in breast and other non-GYN carcinomas other than those primary to the thyroid indicates that anti-PAX-8 is an important new marker of ovarian cancer and a useful marker for the differential diagnoses in lung and neck tumors, or tumors at distant sites where primary lung carcinoma, breast carcinoma or thyroid carcinoma are possibilities. Anti-PAX-8, combined with organ system-specific markers such as anti-uroplakin III, anti-mammaglobin, and anti-TTF-1, can collectively serve as a very useful panel to determine the primary site of invasive micropapillary ovarian carcinomas from invasive carcinomas arising from bladder, lung, and breast.1-9

Specialties: Anatomic Pathology

Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: ovarian carcinoma (non-mucinous carcinoma), thyroid carcinoma, renal cell carcinoma
  • Isotype: IgG
  • Dilution Range: 1:50-1:200*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana ultraView
    UV/CC1M/16min @ 37°C
  • Leica Bond
    Protocol F: ER2/10

Download an IFU

Select revision:


Keycode Specific IFU

Keycode:
Select prefix.
Please verify your keycode and try again. If problems presist contact Customer Service
Enter keycode.
Please verify your keycode and try again. If problems presist contact Customer Service

Some products may have special labeling requirements in the United States.

Are you located in the U.S.?



*Note: IFUs with the prefix RUO or ASR are only available for download in English.


Click here to learn about keycodes

References


  1. Tamara L, et al. Am J Surg Pathol. 2009; 33:1037-41.
  2. Daisuke N, et al. Mod Pathol. 2008; 21:192-200.
  3. Nikiforova MN, et al. Am J Surg Pathol. 2002; 26:1016-23.
  4. Marques AR, et al. J Clin Endocrinol Metab. 2002; 87:3947-52.
  5. Tina DP, et al. J Bio Chem. 2003; 278:3395-3402.
  6. Zhang P, et al. Pathol Int. 2006; 56:240-245.
  7. Bowen NJ, et al. Gynecol Oncol. 2007; 104:331-7.
  8. Nonaka D, et al. Am J Surg Pathol. 2008; 32:1566-71.
  9. Tong GX, et al. Modern Pathology. 2009; 22:1218-1227.

Last updated: 2016-09-29 13:18:40

PAX-8
PAX-8 antibody labels the tumor nuclei in clear cell renal cell carcinoma.

Mouse over to zoom, use scroll wheel to zoom in/out

Tap image once to activate zoom lens


Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: ovarian carcinoma (non-mucinous carcinoma), thyroid carcinoma, renal cell carcinoma
  • Isotype: IgG
  • Dilution Range: 1:50-1:200*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana ultraView
    UV/CC1M/16min @ 37°C
  • Leica Bond
    Protocol F: ER2/10

References


  1. Tamara L, et al. Am J Surg Pathol. 2009; 33:1037-41.
  2. Daisuke N, et al. Mod Pathol. 2008; 21:192-200.
  3. Nikiforova MN, et al. Am J Surg Pathol. 2002; 26:1016-23.
  4. Marques AR, et al. J Clin Endocrinol Metab. 2002; 87:3947-52.
  5. Tina DP, et al. J Bio Chem. 2003; 278:3395-3402.
  6. Zhang P, et al. Pathol Int. 2006; 56:240-245.
  7. Bowen NJ, et al. Gynecol Oncol. 2007; 104:331-7.
  8. Nonaka D, et al. Am J Surg Pathol. 2008; 32:1566-71.
  9. Tong GX, et al. Modern Pathology. 2009; 22:1218-1227.

Download an IFU

Select revision:



Ordering Information

For in vitro diagnostic (IVD) use in USA

DescriptionCat. No.
0.1 ml, concentrate 363M-14
0.5 ml, concentrate 363M-15
1 ml, concentrate 363M-16
1 ml, predilute 363M-17
7 ml, predilute 363M-18
25 ml, predilute 363M-10

For in vitro diagnostic (IVD) use in Canada

DescriptionCat. No.
0.1 ml, concentrate 363M-14
0.5 ml, concentrate 363M-15
1 ml, concentrate 363M-16
1 ml, predilute 363M-17
7 ml, predilute 363M-18
25 ml, predilute 363M-10

For in vitro diagnostic (IVD) use in the EU

DescriptionCat. No.
0.1 ml, concentrate 363M-14
0.5 ml, concentrate 363M-15
1 ml, concentrate 363M-16
1 ml, predilute 363M-17
7 ml, predilute 363M-18
25 ml, predilute 363M-10

For research use only (RUO) in Japan

DescriptionCat. No.
0.1 ml, concentrate 363M-14 (RUO)
0.5 ml, concentrate 363M-15 (RUO)
1 ml, concentrate 363M-16 (RUO)
1 ml, predilute 363M-17 (RUO)
7 ml, predilute 363M-18 (RUO)
25 ml, predilute 363M-10 (RUO)

Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: ovarian carcinoma (non-mucinous carcinoma), thyroid carcinoma, renal cell carcinoma
  • Isotype: IgG
  • Dilution Range: 1:50-1:200*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana ultraView
    UV/CC1M/16min @ 37°C
  • Leica Bond
    Protocol F: ER2/10

Download an IFU

Select revision:


Keycode Specific IFU

Keycode:
Select prefix.
Please verify your keycode and try again. If problems presist contact Customer Service
Enter keycode.
Please verify your keycode and try again. If problems presist contact Customer Service

Some products may have special labeling requirements in the United States.

Are you located in the U.S.?


*Note: IFUs with the prefix RUO or ASR are only available for download in English.



Click here to learn about keycodes

References


  1. Tamara L, et al. Am J Surg Pathol. 2009; 33:1037-41.
  2. Daisuke N, et al. Mod Pathol. 2008; 21:192-200.
  3. Nikiforova MN, et al. Am J Surg Pathol. 2002; 26:1016-23.
  4. Marques AR, et al. J Clin Endocrinol Metab. 2002; 87:3947-52.
  5. Tina DP, et al. J Bio Chem. 2003; 278:3395-3402.
  6. Zhang P, et al. Pathol Int. 2006; 56:240-245.
  7. Bowen NJ, et al. Gynecol Oncol. 2007; 104:331-7.
  8. Nonaka D, et al. Am J Surg Pathol. 2008; 32:1566-71.
  9. Tong GX, et al. Modern Pathology. 2009; 22:1218-1227.
Request More Information